SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Sanofi – ‘6-K’ for 6/30/22

On:  Thursday, 7/28/22, at 10:12am ET   ·   For:  6/30/22   ·   Accession #:  1121404-22-16   ·   File #:  1-31368

Previous ‘6-K’:  ‘6-K’ on 7/28/22 for 6/30/22   ·   Next:  ‘6-K’ on / for 8/8/22   ·   Latest:  ‘6-K’ on / for 9/22/22

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 7/28/22  Sanofi                            6-K         6/30/22    2:1.4M

Current, Quarterly or Annual Report by a Foreign Issuer   —   Form 6-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current, Quarterly or Annual Report by a Foreign    HTML     17K 
                Issuer                                                           
 2: EX-99.1     Miscellaneous Exhibit                               HTML   1.14M 


‘6-K’   —   Current, Quarterly or Annual Report by a Foreign Issuer


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2022

Commission File Number: 001-31368
 
 
SANOFI
(Translation of registrant’s name into English)
 
 
54, rue La Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes  ☐            No  ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- 




In July 2022, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List


Exhibit No.Description
Exhibit 99.1
Press release dated July 28, 2022: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease







Exhibit Index


Exhibit No.Description
Exhibit 99.1
Press release dated July 28, 2022: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 28, 2022SANOFI
By:                              /s/ Alexandra Roger
Name:Alexandra Roger
Title:Head of Securities Law and Capital Markets


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘6-K’ Filing    Date    Other Filings
Filed on:7/28/226-K
For Period end:6/30/226-K
 List all Filings 
Top
Filing Submission 0001121404-22-000016   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2022 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Sep. 27, 2:17:33.1pm ET